DA-1726 Phase 1 IND Filing Expected by Year End 2023
Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi, M.D.
Cash and Cash Equivalents of $25.8 Million, Expected to Fund.
NeuroBo Pharmaceuticals (NRBO) Receives First Site IRB Approval for its Phase 2a Clinical Trial of DA-1241 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Chinese firmâs COVID-19 drug claims draw scientistsâ skepticism By Syndicated Content
By Gabriel Stargardter
(Reuters) â Chinese biotech firm Kintor Pharmaceutical Limited [9939.HK] saw its stock price jump by more than 20% the day after it announced on April 25 that it had âcompleted the first patient enrollment and dosingâ in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the companyâs latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed companyâs stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
Scientists skeptical over Chinese firm s Covid-19 drug claims, firm s stocks surge Reuters Chinese Covid drug
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had "completed the first patient enrollment and dosing" in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.